Herantis Pharma has announced a strategic collaboration with Indivi (a Basel-based techbio company focused on advancing precision medicine in neuroscience drug development) to support its Phase II plans for lead asset, HER-096, in Parkinson’s disease (PD). Under the partnership, Herantis intends to
